The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing projects using artificial intelligence and other technologies in collaboration with the Department of Health and Human Services, the Defense Advanced Research Projects Agency and private sector organizations. The program, called “Equip-A-Pharma,” will address U.S.-based manufacturing of eight sterile injectable or oral drugs and the pharmaceutical ingredients for those medicines.   

Private sector partners conducting the projects are Battelle Memorial Institute and Aprecia, BrightPath Laboratories, Rutgers University and the Mark Cuban Cost Plus Drug Company. Each organization is expected to submit abbreviated new drug applications to the Food and Drug Administration within a year. 

Related News Articles

Headline
In this conversation, Aaron Lewandowski, M.D., emergency medicine physician and the emergency medicine stroke representative at Henry Ford West Bloomfield…
Headline
Cleveland Clinic's Eric Boose, M.D., family medicine physician and associate chief medical information officer and Rohit Chandra, executive vice president and…
Headline
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in…
Perspective
Public
America’s hospitals and health systems are incubators of innovation, ideas and medical progress as they are constantly striving to improve patient care and…
Headline
A ChatGPT vulnerability identified last year is being used by cyberthreat actors to attack security flaws in artificial intelligence systems, according to a…
Headline
In this conversation, Dave Newman, M.D., vice president and chief medical officer for virtual care at Sanford Health, discusses how innovative virtual care…